Skip to main content

ORIGINAL RESEARCH article

Front. Pharmacol.
Sec. Experimental Pharmacology and Drug Discovery
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1540636
This article is part of the Research Topic Promising Photosensitive Agents for Photodynamic Therapy View all 9 articles

Prognostic Value and Immune Landscape Association of LRFN4 in Lung Adenocarcinoma

Provisionally accepted
Nana Wang Nana Wang Shuming Cao Shuming Cao Xiaofeng Tan Xiaofeng Tan Meirong Liu Meirong Liu *
  • Tianjin Hospital, Tianjin, Tianjin, China

The final, formatted version of the article will be published soon.

    Background: LRFN4 is expressed in various tumors and leukemia cell lines. This study aims to explore the effect of LRFN4 in lung adenocarcinoma (LUAD).Methods: The data on LUAD patients were collected from the Cancer Genome Atlas and Gene Expression Omnibus database. The expression of LRFN4 in LUAD and LUAD cell lines was analyzed via differential gene analysis, qRT-PCR assay, and western blotting assay. The correlation of LRFN4 expression with the onset of LUAD were calculated using Pearson correlation analysis. The transcription factors correlated with LRFN4 expression were screened by differential expression analysis and Pearson correlation analysis. Moreover, the effect of LRFN4 on the immune landscape of LUAD was analyzed using CIBERSORT algorithm. The GDSC and CTRP databases were used to analyze the drug sensitivity of hub gene.Results: LRFN4 was highly expressed in LUAD patients and cells, and LRFN4 expression was correlated with metastasis, pathological stages, and age of LUAD patients. The transcription factors E2F1 and E2F3 could regulate LRFN4 expression by binding upstream of LRFN4. The 8 immune cell infiltration levels were differential between LRFN4high and LRFN4low patients. The ESTIMATEScore and ImmuneScore levels were decreased the TumorPurity level was elevated, and 6 immune checkpoint expressions were increased in LRFN4high patients. Moreover, LRFN4high patients had inferior prognosis. The mutation rate of TP53, TTN, and MUC6 and the level of TMB were increased in LRFN4high patients. The expressions of TCF3, E2F1, E2F3, and LRFN4 were correlated with the IC50 of multiple drugs.Conclusion: LRFN4 may serve as a novel prognostic biomarker for LUAD, shows specific overexpression in LUAD and may be a potential therapeutic target for LUAD patients.

    Keywords: LRFN4, Lung Adenocarcinoma, E2F1, E2F3, Immune landscape, drug sensitivity

    Received: 06 Dec 2024; Accepted: 27 Jan 2025.

    Copyright: © 2025 Wang, Cao, Tan and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Meirong Liu, Tianjin Hospital, Tianjin, Tianjin, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.